Exhaled Nitric Oxide : Biomarker of Acute Respiratory Distress Syndrome

Exhaled Nitric Oxide : Biomarker of Acute Respiratory Distress Syndrome

The aim of the study is to see if endogenous exhaled Nitric Oxyde (eNO) concentrations measured are significantly higher in ARDS patients admitted in ICU ; compared to control subjects in good health with no lung disease or global inflammation, operated under general anesthesia (i.e. intubated and ventilated) for thyroid or parathyroid.

The measurement of endogenous exhaled NO is monitored using a laser spectrometer machine connected to the expiratory circuit of the respirator. The measure is non-invasive and made by sampling expiratory gaz like for capnography.

In control subjects, the measurement period corresponds to the first ten minutes after induction of anesthesia (with intubation) before surgical incision.

In ARDS patients in intensive care, the measurement of eNO is made in the first twenty-four hours after intubation and ventilation of the patient with mechanical respirator.

The primary endpoint is a significantly higher eNO concentration in patients suffering from Acute Respiratory Distress Syndrome (ARDS).

Secondary endpoints will assess correlations between eNO concentrations and usual ARDS severity criteria: PaO2/FiO2; ventilator-free days; length of stay in intensive care and all-cause hospital mortality at 30 days.

Inclusion Criteria:

• For ARDS patients :

  • Patients with ARDS (according to the Berlin criteria) admitted in intensive care unit and intubated for less than 24 hours.

• For control patients :

  • Patients with no major disease (classified 1 or 2 in the classification of the American Society of Anaesthesiology)
  • Patients undergoing general anaesthesia for a thyroïd or parathyroïd surgery

Exclusion Criteria:

• Minors under the age of 18 years old
• Pregnant women
• prisoners
• patients who have withdrawn their consent.